Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.62 |
| ▸ | MAOA | P21397 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | GLA | P06280 | 1/20 | 0.58 |
| ▸ | DRD2 | P14416 | 2/20 | 0.56 |
| ▸ | DRD4 | P21917 | 2/20 | 0.56 |
| ▸ | DRD3 | P35462 | 2/20 | 0.56 |
| ▸ | DDX3X | O00571 | 2/20 | 0.54 |
| ▸ | CD74 | P04233 | 1/20 | 0.53 |
| ▸ | MIF | P14174 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.48 |
| ▸ | ESRRA | P11474 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10447579 | 0.91 | NOTUM (0.54) | NOTUMMAOAL3MBTL1GLADDX3X | |
| SCHEMBL15076068 | 0.84 | L3MBTL1 (0.55) | NOTUMMAOAL3MBTL1GLADRD2 | |
| SCHEMBL15075959 | 0.84 | L3MBTL1 (0.55) | NOTUMMAOAL3MBTL1GLADRD2 | |
| SCHEMBL15075954 | 0.84 | L3MBTL1 (0.55) | NOTUMMAOAL3MBTL1GLADRD2 | |
| SCHEMBL3777938 | 0.80 | NOTUM (0.68) | NOTUMMAOAL3MBTL1GLADRD2 | |
| SCHEMBL15316362 | 0.79 | GLA (0.61) | NOTUMMAOAL3MBTL1GLADRD2 | |
| Bromide SCHEMBL1882333 | 0.79 | NOTUM (0.66) | NOTUMMAOAL3MBTL1GLADRD2 | |
| SCHEMBL21787091 | 0.78 | NOTUM (0.70) | NOTUM | |
| SCHEMBL14345608 | 0.77 | AMY1A (0.50) | NOTUMDDX3X | |
| SCHEMBL16284862 | 0.77 | NPC1 (0.52) | NOTUMMAOAL3MBTL1GLADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2024-07-11 | — | — | US | disclosed |
| US-11826435-B2 | Conduritol aziridine derivatives and uses thereof | UNIVERSITY OF SASKATCHEWAN (CA) | 2023-11-28 | — | — | US | disclosed |
| WO-2017100461-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING AN AUXILIARY MOIETY NON-BIOREVERSIBLY LINKED TO AN INTERNUCLEOSIDE PHOSPHATE OR PHOSPHOROTHIOATE | SOLSTICE BIOLOGICS, LTD. (IE) | 2017-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11826435-B2 | Conduritol aziridine derivatives and uses thereof | GAA, MAN2B1, GBA3 | NOTUM 1059/4885MAOA 777/4885L3MBTL1 4857/4885 |
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | NPY1R, NPY2R, NPY4R | NOTUM 4807/4885MAOA 1359/4885L3MBTL1 2541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.